362 related articles for article (PubMed ID: 8128427)
21. Type 2 diabetes: assessment of endothelial lesion and fibrinolytic system markers.
Soares AL; Sousa Mde O; Dusse LM; Fernandes AP; Lasmar MC; Novelli BA; Lages Gde F; Carvalho Md
Blood Coagul Fibrinolysis; 2007 Jul; 18(5):395-9. PubMed ID: 17581312
[TBL] [Abstract][Full Text] [Related]
22. Characterization of the pro-thrombotic state in CAPD patients.
Preloznik Zupan I; Sabovic M; Salobir B; Buturovic Ponikvar J
Ren Fail; 2008; 30(6):597-602. PubMed ID: 18661409
[TBL] [Abstract][Full Text] [Related]
23. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
24. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura.
Wada H; Kaneko T; Ohiwa M; Tanigawa M; Hayashi T; Tamaki S; Minami N; Deguchi K; Suzuki K; Nakano T
Am J Hematol; 1993 Oct; 44(2):101-5. PubMed ID: 8266913
[TBL] [Abstract][Full Text] [Related]
25. Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation.
van Genderen PJ; Lucas IS; van Strik R; Vuzevski VD; Prins FJ; van Vliet HH; Michiels JJ
Thromb Haemost; 1996 Sep; 76(3):333-8. PubMed ID: 8883266
[TBL] [Abstract][Full Text] [Related]
26. [Haemostatic disturbances in essential thrombocythosis].
Rośc D; Gadomska G; Kremplewska-Nalezyta E; Bielis L
Przegl Lek; 2007; 64(3):121-3. PubMed ID: 17941461
[TBL] [Abstract][Full Text] [Related]
27. The effects of sex steroids on plasma levels of marker proteins of endothelial cell functioning.
van Kesteren PJ; Kooistra T; Lansink M; van Kamp GJ; Asscheman H; Gooren LJ; Emeis JJ; Vischer UM; Stehouwer CD
Thromb Haemost; 1998 May; 79(5):1029-33. PubMed ID: 9609242
[TBL] [Abstract][Full Text] [Related]
28. Hemostasis during normal pregnancy and puerperium.
Hellgren M
Semin Thromb Hemost; 2003 Apr; 29(2):125-30. PubMed ID: 12709915
[TBL] [Abstract][Full Text] [Related]
29. Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications.
Erem C; Hacihasanoğlu A; Celik S; Ovali E; Ersöz HO; Ukinç K; Deger O; Telatar M
Med Princ Pract; 2005; 14(1):22-30. PubMed ID: 15608477
[TBL] [Abstract][Full Text] [Related]
30. Dyslipidemias and fibrinolysis.
Puccetti L; Bruni F; Pasqui AL; Pastorelli M; Bova G; Cercignani M; Palazzuoli A; Auteri A
Ital Heart J; 2002 Oct; 3(10):579-86. PubMed ID: 12478815
[TBL] [Abstract][Full Text] [Related]
31. Relationship of homocysteine to markers of platelet and endothelial activation in "high risk" hypertensives: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.
Spencer CG; Martin SC; Felmeden DC; Blann AD; Beevers GD; Lip GY
Int J Cardiol; 2004 Apr; 94(2-3):293-300. PubMed ID: 15093996
[TBL] [Abstract][Full Text] [Related]
32. [Thrombomodulin, von Willebrand factor and tissue plasminogen activator in the blood plasma of obese women and men].
Rość D; Drewniak W; Kinasz-Rózycka I; Kulwas A; Michalski A
Pol Merkur Lekarski; 2003 Dec; 15(90):518-20. PubMed ID: 15058251
[TBL] [Abstract][Full Text] [Related]
33. von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis.
Blann AD; Dobrotova M; Kubisz P; McCollum CN
Thromb Haemost; 1995 Aug; 74(2):626-30. PubMed ID: 8584997
[TBL] [Abstract][Full Text] [Related]
34. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis.
Wållberg-Jonsson S; Cvetkovic JT; Sundqvist KG; Lefvert AK; Rantapää-Dahlqvist S
J Rheumatol; 2002 May; 29(5):875-82. PubMed ID: 12022343
[TBL] [Abstract][Full Text] [Related]
35. Plasma von Willebrand Factor Antigen (vWF:AG) and thrombomodulin (TM) levels in Adult Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndromes (TTP/HUS) and bone marrow transplant-associated thrombotic microangiopathy (BMT-TM).
Zeigler ZR; Rosenfeld CS; Andrews DF; Nemunaitis J; Raymond JM; Shadduck RK; Kramer RE; Gryn JF; Rintels PB; Besa EC; George JN
Am J Hematol; 1996 Dec; 53(4):213-20. PubMed ID: 8948657
[TBL] [Abstract][Full Text] [Related]
36. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
37. Endothelial cell markers (vWF, t-PA and PAI-1) in the elderly.
Gaussem P; Levy C; Verny M; Anglés-Cano E
Thromb Haemost; 1994 Jul; 72(1):164-5. PubMed ID: 7974369
[No Abstract] [Full Text] [Related]
38. The fibrinolytic system in the hemolytic uremic syndrome: in vivo and in vitro studies.
van de Kar NC; van Hinsbergh VW; Brommer EJ; Monnens LA
Pediatr Res; 1994 Aug; 36(2):257-64. PubMed ID: 7970942
[TBL] [Abstract][Full Text] [Related]
39. Plasma thrombomodulin activity, tissue factor activity and high levels of circulating procoagulant phospholipid as prognostic factors for acute myocardial infarction.
Van Dreden P; Rousseau A; Savoure A; Lenormand B; Fontaine S; Vasse M
Blood Coagul Fibrinolysis; 2009 Dec; 20(8):635-41. PubMed ID: 19809306
[TBL] [Abstract][Full Text] [Related]
40. [A clinical study on hemostatic fluctuation during and after cardiopulmonary bypass using hemostatic molecular markers].
Nakajima H
Nihon Kyobu Geka Gakkai Zasshi; 1992 Nov; 40(11):1987-97. PubMed ID: 1336789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
